Encapsulation of Pioglitazone into Polymer–Nanoparticles for Potential Treatment of Atherosclerotic Diseases
Jonas Groner(University of Regensburg), Miriam Breunig(University of Regensburg), Raphael Mietzner(University of Regensburg), Christian E. Ziegler(University of Regensburg), Martina Tognazzi(University of Parma), Daniel F. Fleischmann(German Cancer Research Center), Melanie Walter(The University of Sydney), Achim Goepferich(University of Regensburg)
Cited by 12
Related Papers
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass
|Diabetologia|2010|313
Propionic acidemia: clinical course and outcome in 55 pediatric and adolescent patients
|Orphanet Journal of Rare Diseases|2013|188
IDDM2/insulin VNTR modifies risk conferred by IDDM1/HLA for development of Type 1 diabetes and associated autoimmunity
|Diabetologia|2003|108
Early expression and high prevalence of islet autoantibodies for DR3/4 heterozygous and DR4/4 homozygous offspring of parents with Type I diabetes: The German BABYDIAB study
|Diabetologia|1999|97
Propionic acidemia: neonatal versus selective metabolic screening
|Journal of Inherited Metabolic Disease|2011|91